51
Participants
Start Date
November 30, 2014
Primary Completion Date
May 31, 2015
Study Completion Date
May 31, 2015
Placebo
680 micrograms BID, Orally inhaled placebo for 12 weeks
PF-03715455
680 micrograms BID, Orally inhaled PF-03715455 for 12 weeks
North Shore Long Island Jewish Health System, New Hyde Park
University of Pittsburgh Asthma Institute, Pittsburgh
Chesapeake Clinical Research, Inc., Baltimore
Wake Forest University School of Medicine, Winston-Salem
American Health Research, Charlotte
Upstate Pharmaceutical Research, Greenville
Florida Pulmonary Research Institute, LLC, Winter Park
University of South Florida - Asthma, Allergy and Immunology Clinical Research Unit, Tampa
Clinical Research Center of Alabama, Birmingham
Bernstein Clinical Research Center, Cincinnati
University of Wisconsin School of Medicine & Public Health, Madison
Clinical Research Institute, Minneapolis
Washington University School of Medicine, St Louis
Associated Specialists in Medicine, PC, St Louis
The Clinical Research Center, L.L.C., St Louis
The Asthma and Allergy Center, Bellevue
The Allergy & Asthma Clinic of Central Texas, Killeen
Colorado Allergy and Asthma Centers, PC, Denver
Asthma and Allergy Associates, PC, Colorado Springs
Pulmonary Associates, Pa, Phoenix
California Allergy and Asthma Medical Group, Inc., Los Angeles
Jonathan Corren MD, Inc., Los Angeles
Peninsula Research Associates, Rolling Hills Estates
Allergy Associates Medical Group, San Diego
Integrated Research Group, Incorporated, Riverside
California Research Medical Group, Inc, Fullerton
Little Rock Allergy & Asthma Clinical Research Center, Little Rock
Northeast Medical Research Associates, Inc., North Dartmouth
Lead Sponsor
Pfizer
INDUSTRY